Teva R&D chief out as new CEO picks up the ax and aims at deep cuts to rescue a faltering biopharma — report
Kåre Schultz is once again starting a new job by wielding the ax.
Calcalist is reporting that Teva, which brought Schultz on just a few …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
